Decision: Favourable

Study Title:

Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients. “CARABELA

  • NREC Code:

    21-NREC-CT-130

  • Decision:

    Favourable

  • Meeting Date:

    03/11/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Professor Catherine Kelly

  • PI Institution:

    MMUH

  • Sponsor:

    GEICAM

Scroll to Top
Skip to content